Ranbaxy challenges Pfizer's Lipitor in D. Del.
UPDATE:
Pfizer spokesman Paul Fitzhenry said Pfizer believes that Ranbaxy is infringing on two patents, which will expire in 2009 and 2011, respectively. “Ranbaxy is seeking to sell a generic form of Lipitor and it claims its products will not infringe on our basic patent and that the other patent is invalid,” he said.
0 Comments:
Post a Comment
<< Home